Trial Profile

Randomized Phase 2 Study of Gemcitabine/Cisplatin With or Without SAR240550 (BSI-201), a PARP1 Inhibitor, in Patients With Stage IV Non-small Cell Lung Cancer

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 14 Oct 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Iniparib (Primary) ; Cisplatin; Gemcitabine
Indications Non-small cell lung cancer
Focus Pharmacogenomic; Therapeutic Use
Sponsors Sanofi

Most Recent Events

18 Jul 2019 This trial has been completed in United Kingdom, according to European Clinical Trials Database
24 Mar 2012 This trial is recruiting in France and England.
03 Nov 2011 Status changed from active, no longer recruiting to completed. Initial study results presented at the 2011 European Multidisciplinary Cancer Congress.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com